PL373577A1 - Związki do leczenia chorób proliferacyjnych i zaburzeń komórkowych - Google Patents

Związki do leczenia chorób proliferacyjnych i zaburzeń komórkowych

Info

Publication number
PL373577A1
PL373577A1 PL03373577A PL37357703A PL373577A1 PL 373577 A1 PL373577 A1 PL 373577A1 PL 03373577 A PL03373577 A PL 03373577A PL 37357703 A PL37357703 A PL 37357703A PL 373577 A1 PL373577 A1 PL 373577A1
Authority
PL
Poland
Prior art keywords
compositions
compounds
methods
Prior art date
Application number
PL03373577A
Other languages
English (en)
Other versions
PL211300B1 (pl
Inventor
Andrew Mcdonald
Gustave Bergnes
Bainian Feng
David J.C.Jr. Morgans
Steven David Knight
Kenneth A. Newlander
Dashyant Dhanak
Christopher S. Brook
Original Assignee
Cytokinetics, Inc.
Smithkline Beecham Corporation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics, Inc., Smithkline Beecham Corporation filed Critical Cytokinetics, Inc.
Publication of PL373577A1 publication Critical patent/PL373577A1/pl
Publication of PL211300B1 publication Critical patent/PL211300B1/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/22—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4
    • C07D311/26—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3
    • C07D311/34—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only
    • C07D311/36—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring with oxygen or sulfur atoms directly attached in position 4 with aromatic rings attached in position 2 or 3 with aromatic rings attached in position 3 only not hydrogenated in the hetero ring, e.g. isoflavones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyrane Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
PL373577A 2002-04-17 2003-04-11 Związek i kompozycja zawierająca ten związek PL211300B1 (pl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US37345402P 2002-04-17 2002-04-17
US41068202P 2002-09-13 2002-09-13

Publications (2)

Publication Number Publication Date
PL373577A1 true PL373577A1 (pl) 2005-09-05
PL211300B1 PL211300B1 (pl) 2012-05-31

Family

ID=29254526

Family Applications (1)

Application Number Title Priority Date Filing Date
PL373577A PL211300B1 (pl) 2002-04-17 2003-04-11 Związek i kompozycja zawierająca ten związek

Country Status (21)

Country Link
US (7) US6924376B2 (pl)
EP (1) EP1511734B1 (pl)
JP (1) JP4664597B2 (pl)
KR (1) KR101052816B1 (pl)
CN (1) CN100381437C (pl)
AR (1) AR039419A1 (pl)
AT (1) ATE471931T1 (pl)
AU (1) AU2003234733B2 (pl)
BR (1) BR0309278A (pl)
CA (1) CA2482041C (pl)
DE (1) DE60333094D1 (pl)
DK (1) DK1511734T3 (pl)
IL (2) IL164581A (pl)
MX (1) MXPA04010240A (pl)
MY (1) MY140169A (pl)
NO (1) NO330433B1 (pl)
NZ (1) NZ536190A (pl)
PL (1) PL211300B1 (pl)
RU (1) RU2308454C9 (pl)
TW (1) TWI282337B (pl)
WO (1) WO2003088903A2 (pl)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE471931T1 (de) 2002-04-17 2010-07-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
WO2004006865A2 (en) 2002-07-17 2004-01-22 Cytokinetics, Inc. Compounds, compositions, and methods
JP2005539062A (ja) * 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
AU2004218080B2 (en) * 2003-03-07 2008-01-03 Astrazeneca Ab Novel fused heterocycles and uses thereof
AR050920A1 (es) * 2003-03-07 2006-12-06 Astrazeneca Ab Enantiomeros de heterociclos fusionados seleccionados y usos de los mismos
WO2005042697A2 (en) * 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
WO2005087747A1 (en) * 2004-03-08 2005-09-22 Wyeth Ion channel modulators
BRPI0508594A (pt) * 2004-03-08 2007-08-21 Wyeth Corp moduladores de canal de ìon
CA2564215A1 (en) 2004-05-21 2005-12-01 Chiron Corporation Substituted quinoline derivatives as mitotic kinesin inhibitors
EP1773830A1 (en) * 2004-07-22 2007-04-18 AstraZeneca AB Fused pyrimidones useful in the treatment and the prevention of cancer
US20060041128A1 (en) * 2004-08-18 2006-02-23 Astrazeneca Ab Selected fused heterocyclics and uses thereof
BRPI0514390A (pt) * 2004-08-18 2008-06-10 Astrazeneca Ab enanciÈmero de um composto ou um sal farmacêuticamente aceitável ou um éster hidrolisável in vivo do mesmo, uso do mesmo, métodos para o tratamento de cáncer, para produzir um efeito inibidor de eg5 em um animal de sangue quente e para tratar doenças, e, composição farmacêutica
EP1781673B1 (en) * 2004-08-18 2009-10-21 AstraZeneca AB Selected fused heterocyclics and uses thereof
WO2006060737A2 (en) * 2004-12-03 2006-06-08 Takeda San Diego, Inc. Mitotic kinesin inhibitors
WO2007067752A2 (en) * 2005-12-08 2007-06-14 Cytokinetics, Inc. Certain compositions and methods of treatment
US20090093641A1 (en) * 2006-03-13 2009-04-09 University Of Florida Research Foundation, Inc. Synthesis of Pentafluorosulfanyl (SF5)-Substituted Heterocycles and Alkynes
WO2007134183A2 (en) * 2006-05-13 2007-11-22 Advanced Technology Materials, Inc. Chemical reagent delivery system utilizing ionic liquid storage medium
CA2674318A1 (en) 2007-01-05 2008-07-17 Novartis Ag Cyclized derivatives as eg-5 inhibitors
PT2496567T (pt) 2009-11-05 2017-11-15 Rhizen Pharmaceuticals S A Novos moduladores de quinase benzopiran
SG10202101539RA (en) * 2009-11-05 2021-03-30 Rhizen Pharmaceuticals S A Chromen-4-one Derivatives As Kinase Modulators
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
RS58326B1 (sr) * 2011-05-04 2019-03-29 Rhizen Pharmaceuticals S A Nova jedinjenja kao modulatori proteinskih kinaza
KR101988079B1 (ko) 2012-07-04 2019-06-11 리젠 파마슈티컬스 소시에떼 아노님 선택적 pi3k 델타 억제제
AU2013371541B2 (en) * 2012-12-13 2016-10-13 Glaxosmithkline Llc Enhancer of Zeste Homolog 2 inhibitors
ES2640386T3 (es) 2013-07-10 2017-11-02 Glaxosmithkline Intellectual Property (No. 2) Limited Potenciador de inhibidores del homólogo Zeste 2
JP2018521044A (ja) * 2015-07-23 2018-08-02 ファーマケア，インク． リシルオキシダーゼ様２阻害剤とその使用
AU2017218889A1 (en) 2016-02-09 2018-08-30 Pharmakea, Inc. Quinolinone lysyl oxidase-like 2 inhibitors and uses thereof
CN111991389B (zh) * 2020-09-17 2021-11-23 陕西科技大学 Sb-743921用于制备抗真菌药物的用途

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US55054A (en) * 1866-05-29 Improvement in lamp-chimneys
US116400A (en) * 1871-06-27 Improvement in heels for boots and shoes
US169159A (en) * 1875-10-26 Improvement in corsets
GB728767A (en) * 1951-10-12 1955-04-27 Wander Ag Dr A 2-substituted chromone compounds, and a method of making same
NL84159C (pl) 1952-06-30
EP0020018B1 (en) * 1979-05-19 1983-06-01 Beecham Group Plc Chroman derivatives, processes for their preparation and pharmaceutical compositions containing them
EP0278530A3 (de) 1980-08-30 1989-08-02 Hoechst Aktiengesellschaft Aminosäurederivate, Verfahren zu ihrer Herstellung, diese enthaltende Mittel und deren Verwendung
US4459420A (en) 1982-05-17 1984-07-10 The Upjohn Company Pyrogallol synthesis of anti-atherogenic furochromones
US4434296A (en) 1982-05-17 1984-02-28 The Upjohn Company Process for preparing intermediates for antiatherosclerotic compounds
US4434295A (en) 1982-05-17 1984-02-28 The Upjohn Company Anti-atherosclerotic 6,7-dihydro-7,7-disubstituted-khellin analogs
US4482558A (en) 1982-06-18 1984-11-13 Pfizer Inc. Antifungal amide and urea derivatives of (3-amino-2-aryl-2-hydroxyprop-1-yl)-1H-1,2,4-triazoles
JPS62201882A (ja) * 1985-11-18 1987-09-05 Yamanouchi Pharmaceut Co Ltd イソフラボン誘導体
IN164232B (pl) 1986-04-11 1989-02-04 Hoechst India
IL85554A0 (en) 1987-03-02 1988-08-31 Takeda Chemical Industries Ltd Chromone derivatives
JPH0753725B2 (ja) 1987-10-08 1995-06-07 富山化学工業株式会社 ４ｈ―１―ベンゾピラン―４―オン誘導体およびその塩、それらの製造法並びにそれらを含有する抗炎症剤
MX13485A (es) * 1987-10-19 1993-05-01 Pfizer Procedimiento para obtener tetralinas, cromados y compuestos relacionados, sustituidos
IL89840A (en) 1988-04-06 1996-10-31 Lipha Substituted flavonoid compounds and salts thereof their preparation and pharmaceutical composition containing them
USH1427H (en) 1988-04-06 1995-04-04 Briet; Phillipe Substituted flavonoid compounds, their salts, their manufacture and their use in combination with interleukin-2
US5180717A (en) 1988-08-16 1993-01-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5304548A (en) 1988-08-16 1994-04-19 The Upjohn Company Bivalent ligands effective for blocking ACAT enzyme for lowering plasma triglycerides and for elevating HDL cholesterol
US5284856A (en) 1988-10-28 1994-02-08 Hoechst Aktiengesellschaft Oncogene-encoded kinases inhibition using 4-H-1-benzopyran-4-one derivatives
DE3836676A1 (de) 1988-10-28 1990-05-03 Hoechst Ag Die verwendung von 4h-1-benzopyran-4-on-derivaten, neue 4h-1-benzopyran-4-on-derivate und diese enthaltende arzneimittel
US5703075A (en) 1988-12-21 1997-12-30 Pharmacia & Upjohn Company Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
RU2118321C1 (ru) * 1988-12-21 1998-08-27 Дзе Апджон Компани Замещенные бензопираноны и их фармацевтически приемлемые соли и гидраты
US4977162A (en) 1989-07-13 1990-12-11 Rorer Pharmaceutical Corporation Quinolinyl-chromone derivatives and use for treatment of hypersensitive ailments
US5082849A (en) 1989-07-13 1992-01-21 Huang Fu Chich Quinolinyl-benzopyran derivatives as antagonists of leukotriene D4
US5032598A (en) 1989-12-08 1991-07-16 Merck & Co., Inc. Nitrogens containing heterocyclic compounds as class III antiarrhythmic agents
US5215989A (en) 1989-12-08 1993-06-01 Merck & Co., Inc. Nitrogen-containing heterocyclic compounds as class III antiarrhythmic agents
EP0525123B1 (en) 1990-06-20 1997-09-17 PHARMACIA & UPJOHN COMPANY Antiatherosclerotic and antithrombotic 1-benzopyran-4-ones and 2-amino-1,3-benzoxazine-4-ones
AU650036B2 (en) 1990-07-25 1994-06-09 Teijin Limited Benzopyran derivative, production thereof, and pharmaceutical composition containing the same
US5292916A (en) 1990-09-28 1994-03-08 Ube Industries, Ltd. Method of producing carbonic acid diester
WO1992006086A1 (en) 1990-10-01 1992-04-16 Janssen Pharmaceutica N.V. Novel 4-piperidinylcarbonyl derivatives
JPH05301813A (ja) 1991-10-15 1993-11-16 Kao Corp 皮膚外用剤
DE69330269T2 (de) 1992-01-24 2002-03-14 Teijin Ltd., Osaka Benzopyran-derivate, deren herstellung sowie diese als aktive bestandteile enthaltende arzneimittel
GB9203497D0 (en) * 1992-02-19 1992-04-08 Lilly Industries Ltd Pharmaceutical compounds
US5605896A (en) 1992-02-25 1997-02-25 Recordati S.A., Chemical And Pharmaceutical Company Bicyclic heterocyclic derivatives having α1 adrenergic and 5HT1A activities
FR2693196B1 (fr) 1992-07-03 1994-12-23 Lipha Dérivés de benzopyranone ou de benzothiopyranone, procédé de préparation et composition pharmaceutique les contenant.
JP2579303Y2 (ja) * 1992-08-14 1998-08-27 株式会社共立 バリカン形刈払機
WO1995022992A2 (en) 1994-02-23 1995-08-31 Chiron Corp Method and compositions for increasing the serum half-life of pharmacologically active agents
EP0764159B1 (en) 1994-06-10 2000-08-09 Smithkline Beecham Plc C -4 amide substituted compounds and their use as therapeutic agents
US5607928A (en) 1994-08-05 1997-03-04 Zeneca Limited Carbapenem derivatives containing a bicyclic ketone substituent and their use as anti-infectives
GB9417969D0 (en) 1994-09-07 1994-10-26 King S College London Alkaloids and derivatives thereof
US5602171A (en) 1995-06-07 1997-02-11 Sugen Inc. Methods of inhibiting phosphatase activity and treatment of disorders associated therewith using naphthopyrones and derivatives thereof
WO1997014419A1 (en) 1995-10-20 1997-04-24 Flora Inc. Transdermal delivery of alpha adrenoceptor blocking agents
NL1003520C2 (nl) 1996-07-05 1998-01-07 Stork Amsterdam Sterilisatie-inrichting en werkwijze voor het steriliseren van voorwerpen.
US5908934A (en) 1996-09-26 1999-06-01 Bristol-Myers Squibb Company Process for the preparation of chiral ketone intermediates useful for the preparation of flavopiridol and analogs
JPH10273467A (ja) * 1997-01-29 1998-10-13 Snow Brand Milk Prod Co Ltd 新規テトラロン又はベンゾピラノン誘導体及びその製造方法
GB9807779D0 (en) 1998-04-09 1998-06-10 Ciba Geigy Ag Organic compounds
US6087385A (en) 1998-10-30 2000-07-11 University Of Mississippi Flavonoid derivatives
DE19850131A1 (de) 1998-10-30 2000-05-04 Merck Patent Gmbh Chromenon- und Chromanonderivate
US6028088A (en) 1998-10-30 2000-02-22 The University Of Mississippi Flavonoid derivatives
DE19858341A1 (de) * 1998-12-17 2000-06-21 Merck Patent Gmbh Chromanderivate
US6399633B1 (en) * 1999-02-01 2002-06-04 Aventis Pharmaceuticals Inc. Use of 4-H-1-benzopryan-4-one derivatives as inhibitors of smooth muscle cell proliferation
GB9911071D0 (en) 1999-05-12 1999-07-14 Darwin Discovery Ltd Hydroxamic and carboxylic acid derivatives
AU7080500A (en) 1999-08-27 2001-03-26 Chemocentryx, Inc. Compounds and methods for modulating cxcr3 function
GB9920910D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel chalcones
GB9920912D0 (en) 1999-09-03 1999-11-10 Indena Spa Novel derivatives of flavones,xanthones and coumarins
EP1216234B1 (en) 1999-09-16 2004-12-29 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6552016B1 (en) 1999-10-14 2003-04-22 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
US6545004B1 (en) 1999-10-27 2003-04-08 Cytokinetics, Inc. Methods and compositions utilizing quinazolinones
US6683192B2 (en) 2000-03-30 2004-01-27 Curis, Inc. Small organic molecule regulators of cell proliferation
WO2001083469A1 (en) * 2000-05-03 2001-11-08 Lg Life Sciences Ltd. Cdk inhibitors having 3-hydroxychromen-4-one structure
US6559145B2 (en) 2000-07-12 2003-05-06 Pharmacia & Upjohn Company Heterocycle carboxamides as antiviral agents
DE10036003A1 (de) 2000-07-25 2002-02-14 Aventis Cropscience Gmbh Herbizide Mittel
US6903121B1 (en) 2000-08-17 2005-06-07 Allergan, Inc. Treatment of tumors with acetylenes disubstituted with a phenyl or heteroaromatic group and a substituted chromanyl, thiochromanyl or tetrahydroquinolinyl group in combination with other anti-tumor agents
US6964967B2 (en) 2000-12-11 2005-11-15 Amgen, Inc. Substituted pyrido[2,3-d]pyrimidines and methods for their use
JP2002322169A (ja) 2001-02-21 2002-11-08 Sankyo Co Ltd クロメン誘導体
WO2003011219A2 (en) 2001-07-27 2003-02-13 Curis, Inc. Mediators of hedgehog signaling pathways, compositions and uses related thereto
SE0103648D0 (sv) * 2001-11-01 2001-11-01 Astrazeneca Ab Therapeutic quinolone compounds
EP1444209A4 (en) 2001-11-07 2005-02-16 Merck & Co Inc INHIBITORS OF MITOTIC KINESINS
WO2003049527A2 (en) 2001-12-06 2003-06-19 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE372341T1 (de) 2001-12-06 2007-09-15 Merck & Co Inc Inhibitoren von mitotischem kinesin
JP4391825B2 (ja) 2001-12-06 2009-12-24 メルク エンド カムパニー インコーポレーテッド 有糸分裂キネシン阻害剤
JP2005515208A (ja) 2001-12-06 2005-05-26 メルク　エンド　カムパニー　インコーポレーテッド 有糸分裂性キネシン阻害剤
JP4467979B2 (ja) 2001-12-06 2010-05-26 メルク・シャープ・エンド・ドーム・コーポレイション 有糸分裂キネシン阻害剤
WO2003079973A2 (en) 2002-03-08 2003-10-02 Merck & Co., Inc. Mitotic kinesin inhibitors
ATE471931T1 (de) 2002-04-17 2010-07-15 Cytokinetics Inc Verbindungen, zusammensetzungen und verfahren
US20050234080A1 (en) 2002-05-23 2005-10-20 Coleman Paul J Mitotic kinesin inhibitors
US7301028B2 (en) 2002-06-14 2007-11-27 Merck & Co., Inc. Mitotic kinesin inhibitors
KR20050010515A (ko) 2002-06-14 2005-01-27 머크 앤드 캄파니 인코포레이티드 유사분열 키네신 억제제
WO2004004652A2 (en) 2002-07-08 2004-01-15 Merck & Co., Inc. Mitotic kinesin binding site
WO2004006865A2 (en) 2002-07-17 2004-01-22 Cytokinetics, Inc. Compounds, compositions, and methods
AU2003249534A1 (en) 2002-08-13 2004-02-25 Warner-Lambert Company Llc 6,6-fused heteroaryl derivatives as matrix metalloproteinase inhibitors
JP2005539062A (ja) 2002-09-13 2005-12-22 サイトキネティクス・インコーポレーテッド 化合物、組成物および方法
WO2005042697A2 (en) 2003-10-06 2005-05-12 Cytokinetics, Inc. Compounds, compositions and methods
WO2005040163A1 (en) 2003-10-28 2005-05-06 Dr. Reddy's Laboratories Ltd Heterocyclic compounds that block the effects of advanced glycation end products (age)
JP4502322B2 (ja) 2004-11-08 2010-07-14 Ａｇｃテクノグラス株式会社 ガラス管の曲げ加工方法およびその成形用金型

Also Published As

Publication number Publication date
US7491746B2 (en) 2009-02-17
AR039419A1 (es) 2005-02-16
EP1511734B1 (en) 2010-06-23
US20040082638A1 (en) 2004-04-29
AU2003234733B2 (en) 2009-01-29
IL188954A (en) 2011-02-28
RU2308454C2 (ru) 2007-10-20
BR0309278A (pt) 2005-04-26
MY140169A (en) 2009-11-30
NZ536190A (en) 2007-08-31
KR101052816B1 (ko) 2011-07-29
US20100105767A1 (en) 2010-04-29
RU2004133325A (ru) 2005-10-27
IL164581A0 (en) 2005-12-18
US20130053436A1 (en) 2013-02-28
JP4664597B2 (ja) 2011-04-06
MXPA04010240A (es) 2005-06-08
DK1511734T3 (da) 2010-08-02
PL211300B1 (pl) 2012-05-31
CA2482041A1 (en) 2003-10-30
TWI282337B (en) 2007-06-11
EP1511734A4 (en) 2006-05-10
US20110230550A1 (en) 2011-09-22
JP2005523312A (ja) 2005-08-04
US20120209012A1 (en) 2012-08-16
HK1070656A1 (en) 2005-06-24
ATE471931T1 (de) 2010-07-15
US8633236B2 (en) 2014-01-21
CN1662508A (zh) 2005-08-31
IL164581A (en) 2009-11-18
NO20044662L (no) 2005-01-14
US7629477B2 (en) 2009-12-08
TW200408634A (en) 2004-06-01
CA2482041C (en) 2012-06-05
CN100381437C (zh) 2008-04-16
US20090005580A1 (en) 2009-01-01
NO330433B1 (no) 2011-04-11
US8329928B2 (en) 2012-12-11
WO2003088903A3 (en) 2004-09-30
US20060020008A1 (en) 2006-01-26
KR20050036908A (ko) 2005-04-20
WO2003088903A2 (en) 2003-10-30
US8119678B2 (en) 2012-02-21
US7919524B2 (en) 2011-04-05
AU2003234733A1 (en) 2003-11-03
DE60333094D1 (de) 2010-08-05
US6924376B2 (en) 2005-08-02
RU2308454C9 (ru) 2008-05-10
EP1511734A2 (en) 2005-03-09

Similar Documents

Publication Publication Date Title
AU2003262747A8 (en) Compounds, compositions, and methods
EP1503993A4 (en) COMPOUNDS, METHODS AND COMPOSITIONS
AU2003236527A8 (en) Compounds, compositions, and methods
AU2003265242A8 (en) Compounds, compositions, and methods
AU2003270015A8 (en) Compounds, compositions, and methods
EP1542699A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS OF USE THEREOF
EP1646382A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1692112A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS
AU2003299612A8 (en) Compounds, compositions and methods
IL164581A0 (en) Compounds, compositions and methods
AU2003277079A8 (en) Compounds, compositions, and methods
EP1594849A4 (en) COMPOUNDS, COMPOSITIONS, AND METHODS
PL374833A1 (pl) Związki 5-arylotetrazolowe, ich kompozycje i zastosowania
AU2003290507A8 (en) Compounds, compositions and methods
IL167936A0 (en) Compounds, compositions,and methods
EP1675834A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1680420A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1620092A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
AU2003267169A8 (en) Compounds, compositions and methods
AU2003300031A8 (en) Compounds, compositions, and methods
EP1706111A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1622878A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1622883A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
EP1622613A4 (en) COMPOUNDS, COMPOSITIONS AND METHODS
ZA200409130B (en) Compounds, compositions, and methods.

Legal Events

Date Code Title Description
LAPS Decisions on the lapse of the protection rights

Effective date: 20140411